Subcutaneous immunotherapy using modified Phl p5a-derived peptides efficiently alleviates allergic asthma in mice
To the Editor, Allergen-specific immunotherapy (AIT) is a treatment for allergic airway disease that induces long-term tolerance by repeated allergen injections and induced regulatory T (reg) cells at the expense of Th2 cells. Nonetheless, AIT requires large amounts of allergens that need to be administered over prolonged periods of time and treatment can induce severe side effects. Allergen-derived peptides, encoding the dominant T-cell epitopes, lack the capacity to bind IgE and are a safe alternative. Unfortunately, treatment response to peptide AIT is suboptimal for most allergens. 1, 2 Peptides may have a short half-life after administration and need to be phagocytosed by DCs for presentation to T cells to exert their tolerogenic activity. We have previously designed a novel strategy to increase uptake and presentation of peptides by DCs, while also influencing their tolerogenic phenotype. 3 Dendritic cells (DCs) express sialic acid-binding Ig-like lectins (siglecs), which function as endocytic receptors. In mice, sialylation of antigens has been shown to instruct DCs to manifest an antigen-specific tolerogenic state, enhancing generation of Treg cells while reducing the generation of inflammatory T cells. 4 Therefore, we hypothesize that sialylation of peptides encoding the immunodominant T-cell epitopes from the Phleum pratense 5a allergen (Phl-p5a) has the potential to enhance the efficacy of peptide AIT.
To test our hypothesis, we compared unmodified and sialylated
Phl-p5a-peptides in an experimental grass pollen subcutaneous AIT (GP-SCIT) model, 5 to evaluate whether peptide SCIT is effective in suppressing allergic airway inflammation and whether the use of sialylated peptides leads to increased induction of Tregs and enhanced suppression of allergic phenotypes as compared to the unmodified peptide SCIT.
We first measured T-cell activation by DCs loaded with unmodified or sialylated Phl-p5a peptides in vitro. Next, GP-sensitized mice received SCIT with unmodified or sialylated Phl-p5a peptides (or control) followed by GP challenges to induce allergic airway inflammation. Ear swelling tests were performed, and specific immunoglobulins, airway hyperresponsiveness (AHR), and airway inflammation were measured. 6 Two peptides encoding the immunodominant BALB/c T-cell Phl-p5a epitopes were synthesized, sialylated, and mixed in equimolar ratio for use in the in vitro T-cell stimulations and in our in vivo SCIT model (Figures 1 A-C, S1 ). We observed that GP-specific T cells showed increased proliferation, higher FoxP3 expression, and produced higher TGF-β1 and reduced IL-5 levels in response to Sia-peptide-loaded DCs, as compared to unsialylated controls (Figure 1 B) .
In our in vivo model, (Sia)-peptide SCIT did not affect the GPspecific B-cell response, in contrast to SCIT using GP extracts Whereas the GP-SCIT model is based on the whole GP-extract encompassing all allergens, our peptide SCIT uses two short synthetic peptides based on the major T-cell epitopes in Phl p5a, 7 which might explain why peptide SCIT is not as effective on all parameters as the reference GP-SCIT using crude extracts. It has recently been shown that AIT modifies CD4 + T cells in an epitope-specific manner, resulting in depletion of those T-cell clones that were specifically increased in allergic patients. 8 Therefore, optimal peptide SCIT might require peptide sequences from all major GP allergens. Moreover, since T-cell epitopes are dependent on MHC use, a wider variety of T-cell epitopes will be needed to obtain a formulation that can be applied in most GP allergic individuals, while keeping the peptides as short as possible (20 AA) to prevent IgE cross-linking and adverse events. 7 Consequently, the net dosage of each individual peptide in the mixture used will be relatively low. We postulate that sialylation of the peptides used in such formulations is a valuable approach to increase efficiency of peptide SCIT.
In conclusion, the use of sialylated allergen-derived peptides encoding T-cell epitopes is a promising approach toward efficient and safe AIT treatment regimens. 
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